Serina Therapeutics 過去の業績
過去 基準チェック /06
Serina Therapeutics's earnings have been declining at an average annual rate of -687.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 2368.9% per year.
主要情報
-687.1%
収益成長率
-414.4%
EPS成長率
| Biotechs 業界の成長 | -14.6% |
| 収益成長率 | 2,368.9% |
| 株主資本利益率 | n/a |
| ネット・マージン | -220.9% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
収支内訳
Serina Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -7 | 6 | 0 |
| 31 Mar 24 | 3 | -11 | 5 | 0 |
| 31 Dec 23 | 3 | 5 | 4 | 0 |
| 30 Sep 23 | 0 | 4 | 2 | 0 |
| 30 Jun 23 | 0 | 1 | 2 | 0 |
| 31 Mar 23 | 0 | 0 | 2 | 0 |
| 31 Dec 22 | 1 | -3 | 1 | 0 |
| 31 Dec 21 | 3 | -1 | 1 | 0 |
質の高い収益: 2BO is currently unprofitable.
利益率の向上: 2BO is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: Insufficient data to determine if 2BO's year-on-year earnings growth rate was positive over the past 5 years.
成長の加速: Unable to compare 2BO's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 2BO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
株主資本利益率
高いROE: 2BO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.